Plain-English translation of NCT05873686 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new cancer medication called in people whose advanced cancers have not responded well to standard treatments or who cannot receive them. Researchers will first test increasing doses of the medication to find the safest and most effective amount, then expand the study to treat specific cancer types in patients whose tumors have particular genetic changes. The goal is to understand how well this medication works and what side effects it may cause.
Many advanced cancers stop responding to current treatments, leaving patients with limited options. This medication targets specific genetic changes found in certain cancers, offering a potentially new way to treat people whose tumors have these changes.
You likely qualify if…
You likely don't qualify if…
In the first part of the study, you will take increasing doses of the medication by mouth, starting at 20 mg once daily, while doctors carefully monitor your safety and how your body responds. If the medication appears safe and effective, the second part of the study will treat larger groups of people with specific cancer types that have certain genetic changes. Throughout your participation, you will have regular clinic visits for blood tests, imaging scans, and physical exams to check how well the treatment is working and whether you are experiencing any side effects.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States